Search

Paul V. Ward

Examiner (ID: 4583)

Most Active Art Unit
1624
Art Unit(s)
1624, 1622, 1623
Total Applications
2519
Issued Applications
1801
Pending Applications
239
Abandoned Applications
539

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 18013263 [patent_doc_number] => 11505545 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-11-22 [patent_title] => Anthelmintic quinoline-3-carboxamide derivatives [patent_app_type] => utility [patent_app_number] => 17/085880 [patent_app_country] => US [patent_app_date] => 2020-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 141386 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 2202 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17085880 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/085880
Anthelmintic quinoline-3-carboxamide derivatives Oct 29, 2020 Issued
Array ( [id] => 20226270 [patent_doc_number] => 12414909 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-16 [patent_title] => Polysaccharide-based gelled foam [patent_app_type] => utility [patent_app_number] => 17/772676 [patent_app_country] => US [patent_app_date] => 2020-10-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3194 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 105 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17772676 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/772676
Polysaccharide-based gelled foam Oct 26, 2020 Issued
Array ( [id] => 16612117 [patent_doc_number] => 20210030770 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-04 [patent_title] => LITHIUM CHOLESTEROL COMPOSITIONS, INCLUDING, BUT NOT LIMITED TO LITHIUM CHOLESTEROL SULFATE COMPOSITIONS, AND METHODS OF TREATMENT FOR ALZHEIMER'S DISEASE AND NEUROLOGICAL DISORDERS [patent_app_type] => utility [patent_app_number] => 17/076081 [patent_app_country] => US [patent_app_date] => 2020-10-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23506 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 83 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17076081 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/076081
LITHIUM CHOLESTEROL COMPOSITIONS, INCLUDING, BUT NOT LIMITED TO LITHIUM CHOLESTEROL SULFATE COMPOSITIONS, AND METHODS OF TREATMENT FOR ALZHEIMER'S DISEASE AND NEUROLOGICAL DISORDERS Oct 20, 2020 Abandoned
Array ( [id] => 16749904 [patent_doc_number] => 20210101913 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-08 [patent_title] => 2-OXOTHIATOLE COMPOUNDS HAVING ACTIVITY AS CPLA2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISORDERS AND HYPERPROLIFERATIVE DISORDERS [patent_app_type] => utility [patent_app_number] => 17/076554 [patent_app_country] => US [patent_app_date] => 2020-10-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10928 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17076554 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/076554
2-OXOTHIATOLE COMPOUNDS HAVING ACTIVITY AS CPLA2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISORDERS AND HYPERPROLIFERATIVE DISORDERS Oct 20, 2020 Abandoned
Array ( [id] => 19186231 [patent_doc_number] => 20240165144 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-23 [patent_title] => COMPOSITIONS AND METHODS FOR MODULATING INNATE IMMUNE SIGNALING PATHWAYS [patent_app_type] => utility [patent_app_number] => 17/769517 [patent_app_country] => US [patent_app_date] => 2020-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26456 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17769517 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/769517
COMPOSITIONS AND METHODS FOR MODULATING INNATE IMMUNE SIGNALING PATHWAYS Oct 15, 2020 Abandoned
Array ( [id] => 18056504 [patent_doc_number] => 20220387590 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-08 [patent_title] => PHOTOLYTIC COMPOUNDS AND TRIPLET-TRIPLET ANNIHILATION MEDIATED PHOTOLYSIS [patent_app_type] => utility [patent_app_number] => 17/765251 [patent_app_country] => US [patent_app_date] => 2020-10-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18101 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17765251 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/765251
PHOTOLYTIC COMPOUNDS AND TRIPLET-TRIPLET ANNIHILATION MEDIATED PHOTOLYSIS Oct 6, 2020 Pending
Array ( [id] => 17975513 [patent_doc_number] => 11492361 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-11-08 [patent_title] => Compounds useful in HIV therapy [patent_app_type] => utility [patent_app_number] => 16/948873 [patent_app_country] => US [patent_app_date] => 2020-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 53931 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16948873 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/948873
Compounds useful in HIV therapy Oct 4, 2020 Issued
Array ( [id] => 18018905 [patent_doc_number] => 20220370404 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-24 [patent_title] => PHARMACEUTICAL DRUG CONTAINING HETEROCYCLIDENE ACETAMIDE DERIVATIVE [patent_app_type] => utility [patent_app_number] => 17/766090 [patent_app_country] => US [patent_app_date] => 2020-10-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13306 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17766090 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/766090
PHARMACEUTICAL DRUG CONTAINING HETEROCYCLIDENE ACETAMIDE DERIVATIVE Oct 1, 2020 Pending
Array ( [id] => 16569071 [patent_doc_number] => 20210008077 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-14 [patent_title] => THERAMUTEIN MODULATORS [patent_app_type] => utility [patent_app_number] => 17/038457 [patent_app_country] => US [patent_app_date] => 2020-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23642 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17038457 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/038457
Theramutein modulators Sep 29, 2020 Issued
Array ( [id] => 16581423 [patent_doc_number] => 20210015825 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-21 [patent_title] => THERAMUTEIN MODULATORS [patent_app_type] => utility [patent_app_number] => 17/038353 [patent_app_country] => US [patent_app_date] => 2020-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23644 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17038353 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/038353
Theramutein modulators Sep 29, 2020 Issued
Array ( [id] => 17036643 [patent_doc_number] => 20210253601 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-19 [patent_title] => PYRIMIDINONES AS PI3K INHIBITORS [patent_app_type] => utility [patent_app_number] => 17/038165 [patent_app_country] => US [patent_app_date] => 2020-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35772 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17038165 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/038165
Pyrimidinones as PI3K inhibitors Sep 29, 2020 Issued
Array ( [id] => 18201214 [patent_doc_number] => 11583586 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-02-21 [patent_title] => Methods to induce targeted protein degradation through bifunctional molecules [patent_app_type] => utility [patent_app_number] => 17/035081 [patent_app_country] => US [patent_app_date] => 2020-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 42 [patent_figures_cnt] => 106 [patent_no_of_words] => 42014 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 215 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17035081 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/035081
Methods to induce targeted protein degradation through bifunctional molecules Sep 27, 2020 Issued
Array ( [id] => 17369877 [patent_doc_number] => 20220024929 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2022-01-27 [patent_title] => INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) [patent_app_type] => utility [patent_app_number] => 17/034822 [patent_app_country] => US [patent_app_date] => 2020-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46860 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17034822 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/034822
Inhibitors of cyclin-dependent kinase 7 (CDK7) Sep 27, 2020 Issued
Array ( [id] => 17369877 [patent_doc_number] => 20220024929 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2022-01-27 [patent_title] => INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) [patent_app_type] => utility [patent_app_number] => 17/034822 [patent_app_country] => US [patent_app_date] => 2020-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46860 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17034822 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/034822
Inhibitors of cyclin-dependent kinase 7 (CDK7) Sep 27, 2020 Issued
Array ( [id] => 17974326 [patent_doc_number] => 11491163 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-11-08 [patent_title] => Salt form of a human histone methyltransferase EZH2 inhibitor [patent_app_type] => utility [patent_app_number] => 17/032432 [patent_app_country] => US [patent_app_date] => 2020-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 21 [patent_no_of_words] => 23486 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17032432 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/032432
Salt form of a human histone methyltransferase EZH2 inhibitor Sep 24, 2020 Issued
Array ( [id] => 18036155 [patent_doc_number] => 20220380370 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-01 [patent_title] => XANTHINE CB1 INHIBITORS [patent_app_type] => utility [patent_app_number] => 17/763974 [patent_app_country] => US [patent_app_date] => 2020-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46275 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 195 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17763974 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/763974
XANTHINE CB1 INHIBITORS Sep 24, 2020 Abandoned
Array ( [id] => 18094642 [patent_doc_number] => 20220412983 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-29 [patent_title] => LUMINESCENT COMPOUNDS [patent_app_type] => utility [patent_app_number] => 17/763168 [patent_app_country] => US [patent_app_date] => 2020-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16537 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17763168 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/763168
LUMINESCENT COMPOUNDS Sep 23, 2020 Pending
Array ( [id] => 16710303 [patent_doc_number] => 20210077450 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-18 [patent_title] => TREATMENT FOR OBESITY [patent_app_type] => utility [patent_app_number] => 17/028674 [patent_app_country] => US [patent_app_date] => 2020-09-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10682 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17028674 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/028674
Treatment for obesity Sep 21, 2020 Issued
Array ( [id] => 18085499 [patent_doc_number] => 11535616 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-12-27 [patent_title] => Histone demethylase inhibitors [patent_app_type] => utility [patent_app_number] => 17/026763 [patent_app_country] => US [patent_app_date] => 2020-09-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29229 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17026763 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/026763
Histone demethylase inhibitors Sep 20, 2020 Issued
Array ( [id] => 18097839 [patent_doc_number] => 20220416180 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-29 [patent_title] => O^C^N^N-TYPE TETRADENTATE PLATINUM (II) COMPLEX, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 17/776978 [patent_app_country] => US [patent_app_date] => 2020-09-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3758 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 109 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17776978 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/776978
O^C^N^N-type tetradentate platinum (II) complex, preparation method therefor, and application thereof Sep 18, 2020 Issued
Menu